Meeting U.S. Regulatory Requirements for Clinical Trial Results Disclosure

Introduction: The Importance of Posting Results

Results disclosure is a fundamental component of clinical trial transparency in the United States. While trial registration alerts the public to a study’s existence, posting trial results ensures that the findings—positive or negative—are available for patients, researchers, regulators, and healthcare professionals.

Under FDAAA 801 and the Final Rule (42 CFR Part 11), sponsors and responsible parties must post summary results for applicable clinical trials (ACTs) on ClinicalTrials.gov. Failure to comply can result in legal penalties, public notices of noncompliance, and loss of funding from government agencies like the NIH.

Who Must Report and What Is an Applicable Clinical Trial?

The obligation to disclose results falls on the “responsible party,” usually the trial sponsor or designated principal investigator. This includes:

• Drug, biologic, or device manufacturers sponsoring the study
• Academic institutions leading investigator-initiated trials
• Collaborative groups or consortia listed as sponsors or responsible parties

An Applicable Clinical Trial (ACT) is defined as a controlled clinical study (excluding most Phase I drug trials and small feasibility device studies) involving FDA-regulated products that are not exempt from IND or IDE requirements.

When Must Results Be Submitted?

Results for ACTs must be submitted within 12 months after the “Primary Completion Date”, which is the date when the final subject was examined or received an intervention for the purpose of final collection of data for the primary outcome measure.

In rare cases, responsible parties may request a delay or certification extension—for example, when FDA approval is pending—but these requests are time-bound and must be justified with supporting documentation.

What Must Be Included in Results Submissions?

ClinicalTrials.gov requires a structured and standardized results summary. The following modules must be completed:

• Participant Flow: Number of participants at each trial stage and reasons for dropout
• Baseline Characteristics: Demographics and baseline measures by arm/group
• Outcome Measures: Results for each pre-specified primary and secondary endpoint, including units and statistical analyses
• Adverse Events: Serious and other adverse events categorized by frequency and severity

All information must be entered into structured tables using ClinicalTrials.gov’s web-based submission system or through XML uploads via the Protocol Registration and Results System (PRS).

Adverse Events: Reporting Expectations

Reporting of adverse events is mandatory and includes two main tables:

1. Serious Adverse Events: Events that resulted in death, were life-threatening, required hospitalization, caused disability, or led to birth defects
2. Other (Non-Serious) Adverse Events: Events occurring at or above 5% frequency in any arm/group

Events must be categorized using MedDRA system organ class and preferred terms. If no events occurred, the table must still be submitted with a “0” entry to comply with formatting rules.

Quality Control and Posting Timeline

After submission, ClinicalTrials.gov conducts a Quality Control (QC) review, which typically takes 30–45 days. Sponsors will receive feedback and may need to revise and resubmit data if inconsistencies or missing fields are identified.

Once passed, the data is posted publicly and becomes searchable by the public. As of 2024, ClinicalTrials.gov lists the date results are submitted, posted, and revised, maintaining transparency of sponsor responsiveness.

Case Example: NIH-Funded Trial on Asthma

A multicenter trial funded by the NIH on asthma drug efficacy completed data collection in July 2023. The sponsor submitted results by July 2024 but failed initial QC due to incomplete outcome measure details.

After revision, results were posted in October 2024. Despite the delay, the sponsor avoided penalties by initiating submission on time and responding to QC comments promptly—highlighting the importance of early and complete submission.

Penalties for Late or Incomplete Reporting

The FDA has legal authority to enforce compliance with FDAAA 801. Penalties may include:

• Monetary fines up to $13,237 per day of noncompliance
• Public notices of violation listed on the FDA’s enforcement page
• Loss of eligibility for federal research grants
• Institutional damage to reputation and future partnerships

In 2021, the FDA issued over a dozen noncompliance notices, including to major universities and large CROs. Public enforcement has increased visibility into result posting performance.

Formatting and Common Pitfalls

Common issues that delay posting include:

• Inconsistent unit definitions across arms
• Failure to provide statistical analysis plans or p-values
• Missing denominators in AE tables
• Inadequate explanation of outcome time points

To avoid rejection, sponsors should prepare a results submission plan that mirrors the original protocol endpoints and statistical analysis methods, aligning submitted data with registered outcomes.

Best Practices for Results Disclosure Compliance

• Create a disclosure calendar aligned with your trial milestones
• Start results preparation before trial closeout using draft tables
• Assign roles to trained medical writers or disclosure leads
• Use validation tools provided by PRS to check format before submission
• Maintain internal QC reviews to catch issues prior to external QC

Larger organizations often implement SOPs and templates to streamline submissions and avoid inconsistencies across trial teams.

Conclusion: Transparency Begins with Results

Posting results on ClinicalTrials.gov is not a bureaucratic formality—it’s a legal, ethical, and scientific obligation. With increasing scrutiny from regulators, funders, and the public, trial sponsors must prioritize accuracy, timeliness, and completeness of their results submissions.

By understanding the FDAAA 801 requirements and building internal compliance structures, sponsors can not only avoid penalties but also contribute meaningfully to scientific progress and public trust in medical research.